Key result
Valsartan was generally well tolerated over 18 months in hypertensive children, with 79.3% of patients reporting at least one adverse event (mostly mild or moderate) and no unexpected safety signals.
Cohort (n=150)
Open-label
Yes
Valsartan is generally well-tolerated and provides sustained blood pressure reduction over 18 months in hypertensive children, including those with chronic kidney disease.
Supports tolerability of valsartan in hypertensive children; leaves open need for randomized efficacy and safety trials.
OBJECTIVE: The present study aimed to assess the long-term safety and tolerability of valsartan in hypertensive children aged 6-17 years, with or without chronic kidney disease (CKD). METHODS: This was an 18-month, open-label, multicentre, prospective study conducted in 150 patients with history of hypertension with or without CKD. The primary endpoint was long-term safety and tolerability of valsartan and valsartan-based treatments, assessed in terms of adverse events (AEs), serious AEs, laboratory measurements, estimated glomerular filtration rate (eGFR), urinalysis and electrocardiogram. RESULTS: Of 150 enrolled patients, 117 (78%) completed the study. At week 78, a clinically and statistically significant reduction in mean sitting systolic and diastolic blood pressures was observed in all patients (- 14.9 mmHg and - 10.6 mmHg, respectively). Within the first 3 months of treatment, mean urine albumin creatinine ratio decreased in CKD population, which was sustained. A higher percentage of CKD patients had at least one AE compared to non-CKD patients (85.3% vs. 73.3%, respectively). The majority of AEs were mild (50.7%) or moderate (18.7%) in severity. As expected, in patients with underlying CKD, increases in serum potassium, creatinine and blood urea nitrogen were more commonly reported compared to non-CKD patients. A > 25% decrease in Schwartz eGFR was observed in 28.4% of CKD patients and 13.5% of non-CKD patients. CONCLUSIONS: Valsartan was generally well tolerated, with an AE profile consistent with angiotensin receptor blockers in the overall population and in patients with underlying CKD. Long-term efficacy was maintained and a beneficial effect on proteinuria was observed.
No takes yet. Share an insight, caveat, or question.
Lou‐Meda et al. (2018) conducted a cohort in Hypertension with or without chronic kidney disease (CKD) (n=150). Valsartan was evaluated on Long-term safety and tolerability (incidence of adverse events). Valsartan was generally well tolerated over 18 months in hypertensive children, with 79.3% of patients reporting at least one adverse event (mostly mild or moderate) and no unexpected safety signals.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: